Clinical utility of anti-glycan antibodies in pediatric Crohn's disease in comparison with an adult cohort

Inflammatory Bowel Diseases

Volumn 18, Issue 7, 2012, Pages 1221-1231

  Rieder, Florian ^a,b   Hahn, Philipp ^a   Finsterhoelzl, Lydia ^a   Schleder, Stephan ^a   Wolf, Alexandra ^a   Dirmeier, Andrea ^a   Lopez, Rocio ^b   Shen, Bo ^b   Rogler, Gerhard ^c   Klebl, Frank ^a   Lang, Thomas ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Complications; Fibrosis; Inflammatory bowel disease; Serum antibody; Stricture

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; CHITIN ANTIBODY; CHITOBIOSIDE CARBOHYDRATE ANTIBODY; GLYCAN; GLYCAN ANTIBODY; LAMINARIBIOSIDE CARBOHYDRATE ANTIBODY; LAMINARIN ANTIBODY; MANNOBIOSIDE CARBOHYDRATE ANTIBODY; SACCHAROMYCES CEREVISIAE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; ILEUM DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; ANTIBODIES, ANTI-IDIOTYPIC; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; POLYSACCHARIDES; PROGNOSIS;

EID: 84862218693     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21854     Document Type: Article

References (33)

1. Dubinsky MC, Ofman JJ, Urman M, et al. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol. 2001;96:758-765. (Pubitemid 32240727)
2. Zholudev A, Zurakowski D, Young W, et al. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol. 2004;99:2235-2241. (Pubitemid 39524716)
3. Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology. 1985;88:1818-1825. (Pubitemid 15052293)
4. Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am. 1999;28: 255-281, vii. (Pubitemid 29306479)
5. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004;126:414-424. (Pubitemid 38182298)
6. Dotan I, Fishman S, Dgani Y, et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology. 2006;131:366-378. (Pubitemid 44142445)
7. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005;128:2020-2028. (Pubitemid 40824710)
8. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434. (Pubitemid 47123518)
9. Devlin SM, Dubinsky MC. Determination of serologic and genetic markers aid in the determination of the clinical course and severity of patients with IBD. Inflamm Bowel Dis. 2008;14:125-128; discussion 132-123.
10. Targan SR. The utility of ANCA and ASCA in inflammatory bowel disease. Inflamm Bowel Dis. 1999;5:61-63; discussion 66-67.
11. Sutton CL, Yang H, Li Z, et al. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut. 2000;46:58-63. (Pubitemid 30307678)
12. Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology. 2002;123:689-699. (Pubitemid 34977074)
13. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest. 2004;113:1296-1306. (Pubitemid 39069929)
14. Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous sub-groups with distinct clinical characteristics. Gut. 2000;47:487-496.
15. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007;56:1394-1403. (Pubitemid 47517833)
16. Rieder F, Schleder S, Wolf A, et al. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm Bowel Dis. 2010;16:1367-1375.
17. Rieder F, Schleder S, Wolf A, et al. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior. Inflamm Bowel Dis. 2010;16:263-274.
18. Papp M, Altorjay I, Dotan N, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008;103: 665-681. (Pubitemid 351405992)
19. Seow CH, Stempak JM, Xu W, et al. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol. 2009;104:1426-1434.
20. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis - the Porto criteria. J Pediatr Gastroenterol Nutr. 2005;41:1-7.
21. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
22. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845.
23. Peeters M, Joossens S, Vermeire S, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001;96:730-734. (Pubitemid 32240723)
24. Koutroubakis IE, Petinaki E, Mouzas IA, et al. Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96:449-454.
25. Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol. 2008;6:1105-1111.
26. Amre DK, Lu SE, Costea F, et al. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am J Gastroenterol. 2006;101:645-652. (Pubitemid 43340944)
27. Reumaux D, Sendid B, Poulain D, et al. Serological markers in inflammatory bowel diseases. Best Pract Res. 2003;17:19-35.
28. Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology. 1998;115:822-829. (Pubitemid 28452928)
29. Gupta SK, Fitzgerald JF, Croffie JM, et al. Comparison of serological markers of inflammatory bowel disease with clinical diagnosis in children. Inflamm Bowel Dis. 2004;10:240-244. (Pubitemid 38618253)
30. Ashorn S, Honkanen T, Kolho KL, et al. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:199-205.
31. Markowitz J, Kugathasan S, Dubinsky M, et al. Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology? Inflamm Bowel Dis. 2009;15:714-719.
32. Yu CS, Pemberton JH, Larson D. Ileal pouch-anal anastomosis in patients with indeterminate colitis: long-term results. Dis Colon Rectum. 2000;43:1487-1496.
33. Rieder F, Lopez R, Franke A, et al. Characterization of changes in serum anti-glycan antibodies in Crohn's disease - a longitudinal analysis. PloS One. 2011;6:e18172.